2F5 Stock Overview
A development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Scinai Immunotherapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$7.30 |
| 52 Week Low | US$2.50 |
| Beta | 2.46 |
| 11 Month Change | -8.48% |
| 3 Month Change | -15.17% |
| 1 Year Change | -44.59% |
| 33 Year Change | -98.11% |
| 5 Year Change | -99.40% |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2F5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.0% | -0.7% | -0.02% |
| 1Y | -44.6% | -17.2% | 8.2% |
Return vs Industry: 2F5 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 2F5 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 2F5 volatility | |
|---|---|
| 2F5 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2F5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2F5's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 31 | Amir Reichman | www.scinai.com |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd.
Scinai Immunotherapeutics Ltd. Fundamentals Summary
| 2F5 fundamental statistics | |
|---|---|
| Market cap | €2.43m |
| Earnings (TTM) | -€3.56m |
| Revenue (TTM) | €272.73k |
10.5x
P/S Ratio-0.8x
P/E RatioIs 2F5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2F5 income statement (TTM) | |
|---|---|
| Revenue | US$284.00k |
| Cost of Revenue | US$448.00k |
| Gross Profit | -US$164.00k |
| Other Expenses | US$3.54m |
| Earnings | -US$3.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.42 |
| Gross Margin | -57.75% |
| Net Profit Margin | -1,304.23% |
| Debt/Equity Ratio | -272.1% |
How did 2F5 perform over the long term?
See historical performance and comparison